TherapeuticsJanuary 1, 1995Oral budesonide was less effective, less toxic than prednisolone for Crohn diseaseJoseph J. Nidiry, MD, FACCJoseph J. Nidiry, MD, FACCDiplomate American Board of Internal Medicine and Gastroenterology, Washington, DC, USA (J.J.N.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-1995-122-1-014 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookTwitterLinkedInRedditEmail Source CitationRutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994 Sep 29;331:842-5.References 1 Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-42. Google Scholar2 Feagan BG, Rochon J, Fedorak RN, Irvine EJ, et al., for the North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med. 1995;332:292-7. Google Scholar3 Modigliani R. Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflamm Bowel Dis. 2000;6:251-7. Google Scholar4 Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-9. Google Scholar Author, Article, and Disclosure InformationAffiliations: Diplomate American Board of Internal Medicine and Gastroenterology, Washington, DC, USA (J.J.N.) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails January 1, 1995Volume 122, Issue 1Page: 14KeywordsAbscessesAdverse reactionsCrohn's diseaseDrugsFistulasIleostomyImmunosuppressivesInflammatory bowel diseaseInterleukinsMethotrexateNecrosisPeptic ulcersSafetySurgeryTherapeutic drug monitoringToxicity ePublished: 9 March 2020 Issue Published: January 1, 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.Loading ...